SG Americas Securities’s Apellis Pharmaceuticals APLS Stock Holding History

SG Americas Securities’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$1.29M	–	3355
2026 Q1	$1.29M	Buy	+150,000	New	+$3.23M	﹤0.01%	1602
2024 Q1	–	Sell	-145,000	Closed	-$316K	–	2955
2023 Q4	$316K	Buy	145,000 +131,500	+974%	+$6.67M	﹤0.01%	1793
2023 Q3	$2K	Buy	+13,500	New	+$593K	﹤0.01%	3079
2023 Q2	–	Sell	-300,000	Closed	-$2.19M	–	2274
2023 Q1	$2.19M	Buy	+300,000	New	+$17.3M	0.03%	613

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's APLS Position: Q2 2026 in Review

SG Americas Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 29,601 shares — an estimated $1.19M sold.

SG Americas Securities first reported a position in APLS in Q1 2019 and held it in 28 quarters. The position peaked at $14.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

SG Americas Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 29,601 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
SG Americas Securities first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 28 quarters.
SG Americas Securities's Apellis Pharmaceuticals position peaked at $14.2M in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.